Spot on, primaus72!
R&D expenditures:
FY2021 US$26 MN
FY2022 US$79 MN
FY2023 US$122 MN
FY2024 US$140 MN (e)
FY2025 US$150 MN (e)
All in some US$500-550 MN in total P3 costs, starting from P3 planning in 2H CY2020 down to topline read out mid CY2025.
Important milestone: 90% enrollment achieved, timeline confirmed!, page-7
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
80.0¢ |
Change
-0.035(4.19%) |
Mkt cap ! $984.8M | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 82.8¢ | 80.0¢ | $2.636M | 3.214M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 35676 | 80.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.0¢ | 73544 | 3 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |